IMMUNOMEDICS®, INC.
300 The American Road, Morris Plains, New Jersey 07950 ¤ (973) 605-8200 ¤ Fax (973) 605-8282

NEWS RELEASE

IMMUNOMEDICS ANNOUNCES PRESENTATIONS AT THE 2014 EUROPEAN ASSOCIATION OF NUCLEAR MEDICINE CONGRESS

Morris Plains, NJ, October 13, 2014 --- Immunomedics, Inc., (Nasdaq: IMMU) today announced that 7 studies involving the Companyôs investigational products and technologies will be presented at the 27th Annual European Association of Nuclear Medicine (EANM) Congress, scheduled for October 18 ï 24, 2014, in Gothenburg, Sweden. Details of the presentations are listed below (all times are in Central European Time):

Sunday, October 19, 2014

- Absorbed doses estimations for patients with B-acute lymphoblastic leukaemia treated by radioimmunotherapy with 90Y-epratuzumab tetraxetan (Ferrer, et al.)
  Session: ISTARD - Radionuclide Therapy & Dosimetry: 90Y Dosimetry
  Abstract OP095
  3:14 p.m. - 3:25 p.m.
  Room: G1/G2

Monday, October 20, 2014

- Pretargeted immuno-PET with an anti-carcinoembryonic antigen (CEA) bispecific antibody and a 68Ga-labeled hapten-peptide compared to conventional imaging and FDG-PET in metastatic breast cancer patients (BC): preliminary results (Rousseau, et al.)
  Session: Clinical Oncology: Breast - PET-CT
  Abstract OP299
  2:41 p.m. - 2:52 p.m.
  Room: G4

- Feasibility of pretargeted immuno-PET using an anti-carcinoembryonic antigen (CEA) bispecific antibody and a 68Ga-labeled hapten-peptide in metastatic breast cancer patients (BC): preliminary results (Rousseau, et al.)
  Session: Clinical Oncology: Breast - PET-CT
  Abstract OP300
  2:52 p.m. - 3:03 p.m.
  Room: G4

Tuesday, October 21, 2014

- Pharmacokinetic modelling and optimization of pretargeting using anti-carcinoembryonic antigen (CEA) bispecific antibody and 68Ga-, 111In- or 177Lu-labeled peptide in CEA-positive tumour patients (Barbet, et al.)
  Session: Poster Walk 12 - Biology Track: Miscellaneous
  Abstract PW107
  8:30 a.m. - 8:35 a.m.
  Room: Poster Exhibition Area

~ more ~

- Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer (Lutje, et al.)
  Session: Biology Track - Basic Oncology: Preclinical Imaging 2
  Abstract OP518
  2:30 p.m. - 2:41 p.m.
  Room: G3

Wednesday, October 22, 2014

- High sensitivity of pretargeted immuno-PET using anti-carcinoembryonic antigen (CEA) bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma (MTC) patients (Bodet-Milin, et al.)
  Session: Clinical Oncology: Thyroid & CMT
  Abstract OP695
  10:33 a.m. - 10:44 a.m.
  Room: F6

- Pretargeted immuno-PET using anti-carcinoembryonic antigen (CEA) bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma (MTC) patients: preliminary results of an optimization clinical study (Bodet-Milin, et al.)
  Session: Clinical Oncology: Thyroid & CMT
  Abstract OP696
  10:44 a.m. - 10:55 a.m.
  Room: F6

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedicsô advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or ñnakedò form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of nine clinical-stage product candidates. Immunomedics has an ongoing collaboration with UCB, S.A. (UCB), to whom the Company licensed epratuzumab for the treatment of all non-cancer indications worldwide. UCB expects Phase 3 data in systemic lupus erythematosus in the first half of 2015. Immunomedics is exploring epratuzumab in oncology in collaboration with independent cancer study groups. Immunomedicsô most advanced candidate to which it retains worldwide rights for all indications is ^{90}Y-clivatuzumab tetraxetan. The Company initiated a Phase 3 registration trial in January 2014 in patients with advanced pancreatic cancer and expects topline data in mid-2016. Immunomedicsô portfolio of wholly owned product candidates also includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxic effects that are usually found with conventional administration of these chemotherapeutic agents. Immunomedicsô most advanced ADCs are IMMU-132 and IMMU-130, which are in Phase 2 trials for a number of solid tumors and metastatic colorectal cancer, respectively. Immunomedics also has a number of other product candidates that target solid tumors and

hematologic malignancies, as well as other diseases, in various stages of clinical and pre-clinical development. These include bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its patented DOCK-AND-LOCK® protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 258 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. Immunomedicsô strength in intellectual property has resulted in a top-8 ranking in the Biotechnology industry by the Patent Board for the 2014 fiscal year. For additional information on the Company, please visit its website at www.immunomedics.com. The information on its website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, outcomes, timing or associated costs), out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on UCB for the further development of epratuzumab for non-cancer indications, risks associated with the outcome of pending litigation, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

For More Information:
Dr. Chau Cheng
Senior Director, Investor Relations & Grant Management
(973) 605-8200, extension 123
ccheng@immunomedics.com

###